Pfizer releases vaccine data for 5-11 age group, affirms safety and efficacy
Pfizer today released the first data evaluating a COVID-19 vaccine’s safety and effectiveness for children between the ages of 5 and 11. The data, culled from a phase 2/3 trial, indicates that two, 10-microgram doses of Pfizer’s mRNA vaccine, administered 21 days apart, resulted in a strong immune response against SARS-CoV-2. Pfizer said the data would be included in a “near-term” application to the Food and Drug Administration for emergency use authorization in the 5-11 age group. The drug maker also indicated that it would soon have sufficient trial data for children under 5 for submission to FDA.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…